AI Analysis AI Analysis of PHVS AI-Powered Market Insights
Stock Analysis PRO New!
Risk Assessment PRO New!
Trading Strategy PRO New!
Add PHVS to Watchlist?
Some Reasons Why To Add PHVS:
  • Lower volatility than the market (beta -2.34)
  • Low bankruptcy risk (Altman Z-Score: 50.53)
  • Bullish trend confirmed on both short and long timeframes
PDF

Pharvaris B.V. stock price ended at $35.07 on Monday, after losing 0%
(Updated on Jul 13, 2026)

Buy or Hold candidate since Jun 03, 2026 Gain 16.36%

No changes to the price of Pharvaris B.V. stock on the last trading day (Monday, 13th Jul 2026). During the last trading day the stock fluctuated 3.87% from a day low at $33.83 to a day high of $35.14. The price has fallen in 5 of the last 10 days but is still up by 3.12% over the past 2 weeks.

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 21.29% during the next 3 months and, with a 90% probability hold a price between $38.56 and $43.87 at the end of this 3-month period.

PHVS Signals & Forecast

There are mixed signals in the stock today. A sell signal was issued from a pivot top point on Thursday, July 09, 2026, and so far it has fallen -2.47%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while price remained unchanged. This may be an early warning, but it may also not. We still recommend that you pay attention over the next couple of days. The Pharvaris B.V. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $34.81 and $32.32. A breakdown below any of these levels will issue sell signals.

Support, Risk & Stop-loss for Pharvaris B.V. stock

Pharvaris B.V. finds support from accumulated volume at $34.59 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.31 between high and low, or 3.87%. For the last week, the stock has had daily average volatility of 5.08%.

Our recommended stop-loss: $33.46 (-4.59%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 2 days ago.)

Trading Expectations (PHVS) For The Upcoming Trading Day Of Tuesday 14th

For the upcoming trading day on Tuesday, 14th we expect Pharvaris B.V. to open at $34.68, and during the day (based on 14 day Average True Range), to move between $34.27 and $35.87, which gives a possible trading interval of +/-$1.59 (+/-4.65%) up or down from last closing price. If Pharvaris B.V. takes out the full calculated possible swing range there will be an estimated 4.65% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $34.59 (1.37%) than the resistance at $35.93 (2.44%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Pharvaris B.V. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Pharvaris B.V. stock to perform well in the short-term.

Current score: 1.906 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on July 14, 2026 - $34.68 ( 1.11%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* eToro
*Your capital is at risk

PHVS Performance

Trading levels for PHVS

StockInvest.us
Full Access. No Commitment. 7 Days Free!
Long & Short-Term Golden Star Lists
AI Stock Analysis*
Top 10 Candidates on Every List
Premium Lists
Ad-FREE Browsing
Advanced Stock Screener

Fibonacci Support & Resistance Levels

Level Price
R3 35.99 2.62%
R2 35.49 1.20%
R1 35.18 0.315%
Price 35.07
S1 34.18 -2.54%
S2 33.87 -3.42%
S3 33.37 -4.85%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 35.96 2.54%
R1 35.93 2.44%
Price 35.07
S1 34.59 -1.37%
S2 34.58 -1.40%
S3 30.02 -14.40%

FAQ

What is the symbol for Pharvaris B.V. Stock and on which exchange is it traded?
The symbol for Pharvaris B.V. is PHVS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Pharvaris B.V. Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Pharvaris B.V. stock to perform well in the short-term.

How to buy Pharvaris B.V. Stock?
Pharvaris B.V. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Pharvaris B.V. Stock.

What's the current price of Pharvaris B.V. Stock?
As of the end of day on the Jul 13, 2026, the price of an Pharvaris B.V. (PHVS) share was $35.07.

What is the 52-week high and low for Pharvaris B.V. Stock?
The 52-week high for Pharvaris B.V. Stock is $36.60 and the 52-week low is $19.12.

What is the market capitalization of Pharvaris B.V. Stock?
As of the Jul 13, 2026, the market capitalization of Pharvaris B.V. is 2.451B.

When is the next earnings date for Pharvaris B.V.?
The upcoming earnings date for Pharvaris B.V. is Aug 11, 2026.
Click to get the best stock tips daily for free!
ABOUT PHARVARIS B.V.
Pharvaris B.V
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...
GOLDEN STAR
Ticker Change Signal Date
SRPT
$17.02
10.58% Jun 29
NMRK
$15.02
0.466% Jun 24
X
XMAX
$8.34
2.40% Jun 24
NESR
$25.07
12.49% Jun 23
CAG
$13.43
6.70% Jun 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE